Personalized medicine is a medical model that uses medical decisions, practices, interventions and/or products that are tailored to the individual patient based on their predicted response or risk of disease.

RSK Medical Inc. brings a wealth of experience, knowledge, progressive learning and keen responsiveness as a medical device supplier and is dedicated to providing innovative and disruptive medical device technologies to the Canadian clinical community. These provide clinicians and hospitals with improved outcomes, preventative and therapeutic long-term care for their patients.

Based on strong clinical data and engineering, our products create and deliver substantial economic value to the health care system.

Latest News

ABYRX- MONTAGE Sternal Bone Putty

June 26th, 2024

RSK Medical Inc. is pleased to announce the representation of MONTAGE XT, a settable, resorbable, hemostatic bone putty manufactured by Abyrx Inc. for sternal closure after open heart surgery to be used with sternotomy wires and/or sternal plates.

This bioabsorbable polymer is Health Canada and FDA cleared with over 35,000 patient applications in cranial, spinal, and orthopedic procedures.

Packaged as two putties, it forms a uniform putty when mixed for at least 45 seconds, hardening within 4 minutes. It adheres and expands up to 10% into surrounding porosity, resorbing during bone remodeling over a year.

Read more…

Nationwide distribution agreement with Occlutech

April 17th, 2024

RSK Medical is pleased to announce a new nationwide distribution agreement with Occlutech (Sweden), a leading specialist of minimally invasive cardiac devices effective May 1st, 2024.  Occlutech has developed, manufactured and commercialized minimally invasive implants for over 20 years.  They offer a broad and proven portfolio designed to address Congenital Heart Disease, Stroke Prevention & Adult Intervention and Heart Failure with PFO, ASD and VSD devices.

Read more: Occlutech website

First Use of ANGIODROID Automated Carbon Dioxide Angiography Injector

February 7th, 2024

RSK Medical Inc. is pleased to announce the completion of the first 8 ANGIODROID CO2 Injector cases in Canada in Interventional Radiology at the Centre hospalitalier de l’Université de Montreal (CHUM) last week under the Health Canada Special Access program. A variety of patients received venous or arterial CO2 angiograms due to restrictions related to the use of contrast media.

Thank you to Drs. Bouchard, Therasse, Perrault, Amaral and the Radiology hospital administration and their full clinical team for their great support.

CO2 angiography is an effective alternative to iodine without the risk of further impairment of renal function providing excellent imaging, improved safety and saves costs by using less iodine accompanied by fewer related complications.

Our People

Scott Kadwell

Scott Kadwell is the PRESIDENT of RSK Medical Inc. With over 40+ years in the cardiovascular medical device business in Canada, he has held senior national business and marketing management positions with many of the largest global medical device companies such as SulzerMedica, Guidant, BSC, Medtronic and Sorin Group while residing in Calgary, Vancouver and Toronto.

The cardiovascular specialities related to his experience have been in the fields of interventional cardiology and radiology, electrophysiology, cardiac surgery and vascular/ endovascular therapies.

Scott was formerly an active member at MEDEC Association participating in a number of committees to develop policies, therapy awareness and financial reimbursement for new device technologies.

Greg Whitwham

Greg Whitwham is the “DIRECTOR of Sales” in a full-time consultant role to RSK Medical Inc. Greg is responsible for sales nationwide across the interventional cardiology, radiology and vascular/cardiac surgery product areas.

Greg joined the RSK Medical team with significant medical device industry experience working for companies like Getinge as a Territory Manager, Olympus Corporation as Marketing Manager and Product Manager and Stryker as a Product Manager.

His educational background comes from the University of Western Ontario (London) including both a Bachelor of Engineering Science (Mechanical) and a Bachelor of Science (Medical Biophysics).

Dr. Frederick Kozak

Dr. Frederick Kozak is a Pediatric Otolaryngologist at BC Children’s Hospital and Clinical Professor in the Department of Surgery at the University of British Columbia. In his career of over twenty years, Dr. Kozak has been extensively involved as a clinician, researcher, medical educator and administrator.

His main clinical area of interest is hearing loss in the pediatric population and he is the Surgical/Medical Director of the Pediatric Cochlear Implant Program in B.C. He has published over 40 peer reviewed publications and he has presented his research and educational expertise locally, nationally and internationally. His extensive involvement in administrative committees includes being Vice-Chair and Chair of the Medical Advisory Committee for Children’s and Women’s Hospital of BC from 2002-2007.

Dr. Kozak has provided consultation to several pharmaceutical and device manufacturers over the past 20 years.

Gordon Collins

Gordon Collins is a Business Advisor, Executive Coach and Facilitator. Gordon is the president and founder of The Coaching Network based in Oakville, Ontario. He is also an associate with SGA – a consulting firm specializing in developing ‘C-Suite’ influencing capabilities globally and an adjunct faculty member of the Telfer Centre for Executive Leadership – University of Ottawa.

Gordon specializes in developing Business Effectiveness – through building leadership capability, creating team alignment and designing innovative approaches to creating competitive advantage. He has in-depth experience in the Private, Public and Non Profit sectors as well as a global practice across North and South America, Europe, Middle East, Asia Pacific and Africa.

Gordon has provided consultation to a large number of medical device, biotech and pharmaceutical companies across North America and Europe over the past 20 years.